Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Cash (2016 - 2025)

Historic Change in Cash for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Change in Cash rose 37467.8% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 32448.93%. This contributed to the annual value of -$3.6 million for FY2024, which is 9936.46% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Change in Cash stood at $47.6 million, which was up 37467.8% from -$15.6 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Change in Cash high stood at $84.1 million for Q1 2023, and its period low was -$565.5 million during Q2 2023.
  • In the last 5 years, Ironwood Pharmaceuticals' Change in Cash had a median value of $19.9 million in 2025 and averaged -$11.8 million.
  • Examining YoY changes over the last 5 years, Ironwood Pharmaceuticals' Change in Cash showed a top increase of 41444.43% in 2023 and a maximum decrease of 53530.32% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Change in Cash stood at $45.9 million in 2021, then surged by 78.87% to $82.0 million in 2022, then crashed by 123.54% to -$19.3 million in 2023, then surged by 101.8% to $348000.0 in 2024, then skyrocketed by 13565.23% to $47.6 million in 2025.
  • Its last three reported values are $47.6 million in Q3 2025, -$15.6 million for Q2 2025, and $19.9 million during Q1 2025.